Abstract
Meeting abstracts Generation of a therapeutic immune response against a diverse set of antigens expressed by a patient's cancer is a central goal of cancer immunotherapy. This goal is important because diverse responses may prevent escape of antigen loss variants. To accomplish this goal we have
Highlights
Generation of a therapeutic immune response against a diverse set of antigens expressed by a patient’s cancer is a central goal of cancer immunotherapy. This goal is important because diverse responses may prevent escape of antigen loss variants. To accomplish this goal we have developed tumor-derived autophagosome-enriched vaccines, “DRibbles”, that sequester a complex mixture of proteins including cancer antigens and damage-associated molecular pattern molecules (DAMPs)
DRibble vaccines are superior to whole tumor vaccines in both protection and therapy studies, and demonstrated efficacy even when used across a complete MHC mismatch, opening the way for a clinical off-the-shelf cancer vaccine
UbiVac has produced an allogeneic DRibble vaccine (DPV-001) from two human NSCLC cell lines - UbiLT3 and UbiLT6 - that is currently used in a phase II trial for definitively treated stage IIIA/B NSCLC
Summary
Generation of a therapeutic immune response against a diverse set of antigens expressed by a patient’s cancer is a central goal of cancer immunotherapy. DPV-001 an autophagosome-enriched cancer vaccine in phase II clinical trials contains 25 putative cancer antigens, DAMPS, HSPS and agonists for TLR 2, 3, 4, 7 and 9 From Society for Immunotherapy of Cancer 28th Annual Meeting National Harbor, MD, USA.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
